Revance Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Tennessee, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1222 Demonbreun St Fl 20, Nashville, Ten...Phone Number
(877) 373-8669Website
www.revance.comRevenue
$251.2 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
2
1
1
About Revance Therapeutics
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark,...Explore more
Revance Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Revance Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Revance Therapeutics has new funding data
Click to see if Revance Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Revance Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Revance Therapeutics is spiking on competitors!
Product Launch: Get notified when Revance Therapeutics launches new products
Check if Revance Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Revance Therapeutics recently announced quarterly report
Revance Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Revance Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Revance Therapeutics
Compare insights from companies similar to Revance Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Revance Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Revance Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Revance Therapeutics.
Revance Therapeutics financials insights
Gather financial insights about Revance Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series A
$1.8M
2004
Series B
$13M
2007
Series C
$43.2M
2011
Series D
$45M
2013
Series E
$33M
2014
Stock Offering
$96M
2022
Debt
$300M
Revance Therapeutics Tech Stack
A closer look at the technologies used by Revance Therapeutics
Most Recent Scoops
Hiring Plans
Revance Therapeutics has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Packaging Operations Management.
Hiring Plans
Open Position
Open Position
Hiring Plans
Revance Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Neurology, Botulinum Toxin, Drug Development, Clinical Trials, Medical Devices, Clinical Practices, and Pharmaceuticals.
Hiring Plans
New Hire
Executive Move
Executive Moves, New Hire
Revance Therapeutics News & Media
Revance Appoints Melissa O'Connor as Senior Vice President, Global Regulatory
NASHVILLE, Tenn., Aug. 24, 2026 /PRNewswire/ -- Revance, a fast-growing global leader in aesthetics and skincare, today announced the appointment of Melissa O'Connor as Senior Vice President, Global Regulatory. Ms. O'Connor will report directly to Nick Crowe, Chief Operating Officer –...Revance and Teoxane Announce the FDA Approval of RHA Redensity® Eye for Undereye Hollowing
RHA Redensity Eye delivers natural-looking results that last up to 12 months in the infraorbital hollows.1 NASHVILLE, Tenn., Aug. 20, 2026 /PRNewswire/ -- Revance and Teoxane announce the FDA approval of RHA Redensity Eye from the Teoxane RHA® Collection for the correction of moderate to...Revance Announces Appointment of Janelle Wichmann as Chief Marketing Officer, Skincare
NASHVILLE, Tenn., Aug. 17, 2026 /PRNewswire/ -- Revance, a fast-growing global leader in aesthetics and skincare, today announced the appointment of Janelle Wichmann as Chief Marketing Officer, Skincare. Ms. Wichmann will report directly to Nadeem Moiz, Chief Executive Officer – Revance....The PanOxyl® Brand Strengthens Market Leadership with Expansion into High-Growth Sulfur Segment and New Maximum-Strength Acne Care Innovation
PanOxyl expands as The Acne Authority® brand with the launch of the Pore Refining Mask and Acne Clearing Spot Treatment. NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Revance announced a significant expansion of its award-winning consumer skincare portfolio with the launch of two...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Revance Therapeutics
Sign Up For FreeTo access detailed company insights
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) li... Read More
